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Abstract   
Background: Mobile technology may help to better understand the adherence to treatment MASK-
rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centered ICT system. A 
mobile phone app (the Allergy Diary) central to MASK is available in 22 countries.  
Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary 
App.   
Methods: An observational cross-sectional study was carried out on all users who filled in the 
Allergy Diary from January 1, 2016 to August 1, 2017. Secondary adherence was assessed by using 
the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) 
approach. 
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Results: 12,143 users were registered. 6,949 users reported at least one VAS data recording. Among 
them, 1,887 users reported ≥ 7 VAS data. 1,195 subjects were included in the analysis of adherence. 
136 (11.28%) users were adherent (MPR ≥70% and PDC ≤ 1.25), 51 (4.23%) were partly adherent 
(MPR ≥70% and PDC =1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users 
were non-adherent to medications (MPR<70%). Of those, the largest group was non-adherent to 
medications and the time interval was increased in 442 (36.68%) users.   
Conclusion and clinical relevance: Adherence to treatment is low. The relative efficacy of 
continuous versus on-demand treatment for AR symptoms is still a matter of debate.This study 
shows an approach for measuring retrospective adherence based on a mobile app. This represent a 
novel approach also for analyzing medication taking behavior in a real-world setting. 
 
Key words: mHealth, mobile technology, adherence, rhinitis, treatment, observational study 
 
Abbreviations 
AR: Allergic rhinitis 
ARIA: Allergic Rhinitis and Its Impact on Asthma 
MASK: Mobile ARIA Sentinel networK 
mHealth: mobile health 
MPR: Medication Possession Ratio 
OTC: Over the counter 
PDC: Proportion of Days Covered 
QOL: Quality of life 
VAS: Visual analogue scale 
 
Introduction   
Globally, non-adherence to medications is a major obstacle to the effective delivery of health 
care. Medication adherence and medication persistence are two different constructs. Medication 
adherence is defined as an active, cooperative and voluntary participation of the patient on 
following recommendations from a healthcare provider. This is a multifactorial behaviour that 
involves three critical steps, including initiation, implementation and discontinuation (1). Medication 
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persistence refers to the act of continuing the treatment for the prescribed duration (2). In research 
employing electronic databases in pharmacies, primary adherence assesses whether the patient 
received the first prescription whereas secondary adherence is an ongoing process that measures 
whether the patient received dispensing or refills as prescribed during a defined observation period 
(3). Medication persistence implies that the patient must have exhibited at least primary adherence, 
as it cannot be measured unless the patient has received the first dispensing (3). The two most 
commonly used secondary adherence medication measures are the Medication Possession Ratio 
(MPR) and the Proportion of Days Covered (PDC) (2). These two measures are closely related as they 
are both refill record-based adherence measurements.  
Many mobile phone apps are available to support people in taking their medications and to 
therefore improve medication adherence (4,5). However, a recent meta-analysis found that the 
majority did not have many of the desirable features and were of low quality (4).  
It is known that adherence to treatment is low in allergic diseases and asthma (6,7). Mobile 
technology may help to better understand the adherence and its determinants as well how to 
improve adherence to treatment (8). MPR and PDC are of interest. They have been applied on 
mobile technology (9) but cannot be used directly in anonymized app users as there is usually no 
information on prescription. Thus, the concepts of MPR and PDC should be modified when using 
data gathered from such apps. 
MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centered ICT 
(information and communication technologies) system (10). A mobile phone app (the Allergy Diary) 
central to MASK is available in 22 countries. It has been validated (11) and was found to be an easy 
and effective method of assessing symptoms of AR and work productivity (11-14). MASK follows the 
checklist for the evaluation of Good Practices developed by the European Union Joint Action JA-
CHRODIS (Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle) (15). 
The aim of this study was to assess the adherence to treatment in allergic rhinitis patients using the 
Allergy Diary App.  
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Methods   
Design of the study 
An observational cross-sectional study was carried out on all users who filled in the Allergy Diary 
from January 1, 2016 to August 1, 2017. Five visual analogue scales (VAS) assessed the daily control 
of the disease (i.e. global evaluation of allergic symptoms, nose, eyes, asthma and work) (16). Since 
users are anonymized and cannot be contacted, we could not use an adherence questionnaire such 
as the Morisky (17,18). The paper was written according to the STROBE checklist. 
Inclusion criteria: people who had allergic rhinitis, who used the Allergy Diary, who completed at 
least 7 days (not necessarily consecutive) of symptom recording (VAS global score), and who 
continued to use the same AR medication over the study period. 
Setting  
Users from 22 countries filled in the Allergy Diary (Table 4). The Allergy Diary is available in 16 
languages (translated and back-translated, culturally adapted and legally compliant). 
Users  
All consecutive users who registered to the Allergy Diary were included if they had filled in the VAS 
global measured. The Allergy Diary is filled in independently from the presence/absence of 
symptoms. There were no exclusion criteria for participation in the Allergy Diary initiative. Basic 
demographic characteristics (age, sex, country and language) were recorded. The Allergy Diary was 
used by people who found it on the internet, Apple store, Google Play or in any other way. Some 
users were patients who were asked by their physicians to use the app. However, due to 
anonymization of data, specific information could not be gathered as previously described in detail 
(12,13). The diagnosis of allergic rhinitis is based on the question “I have allergic rhinitis” but all 
users had rhinitis symptoms (11-14). 
Allergy Diary and outcomes 
The Allergy Diary collects information on AR symptoms experienced (nasal and ocular), disease type 
(intermittent/persistent), how symptoms impact users’ lives, and type(s) of AR treatment used. 
Geolocalized users assess their daily symptom control via the touchscreen functionality on their 
smart phone: they click on 5 consecutive VAS measures (VAS-global measured, VAS-nasal, VAS-
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ocular, VAS-asthma and VAS-work). Levels range from zero (not at all bothersome) to 100 (very 
bothersome). Independency of VAS questions was previously assessed using the Bland and Altman 
regression analysis (13,19). Users input their daily medications using a scroll list which contains all 
country-specific OTC and prescribed medications available (Figure 1 online). The list has been 
populated using IMS data. 
Some of the VAS data used in this study have been analyzed in other studies with a different aim 
including work productivity (12) and assessment of treatment or multimorbidity (papers submitted). 
Moreover, the time frame of the three other studies was different. 
Ethics 
The Allergy Diary is CE1 registered. The terms of use have been translated into all languages and 
customized according to the legislation of each country. This thereby allows the use of the results for 
research purposes. The data are anonymized - including the geolocalized data - using k-anonymity 
(20-22). An Independent Review Board approval was not needed for this observational study. 
Assessment of adherence 
1- Definitions used: Several adherence calculation methods are based on tablet counts, electronic 
monitoring by medication containers, patient diaries, and use of adjudicated prescription claims 
from administrative databases. However, using the Allergy Diary, MPR and PDC with the IPSOR 
terminology cannot be directly calculated using a classical method (23). They can however be 
approached. In the present paper, we used: 
 Proportion of medication possession ratio (modified MPR): ratio of days that medication 
was reported to be used on days in a given time interval (see definitions 2 and 3 for further 
details) 
 Proportion of days covered over a time interval (modified PDC): ratio of days that 
medication was reported to be used on days in the time interval between the first and the 
last record considered (i.e. the first and the last day in which the VAS about symptoms 
control is filled in) 
2- Number of days with VAS reported: a cut-off of at least 7 records of VAS was set up to ensure an 
adequate amount of data which assess adherence. Therefore, only users matching this cut-off were 
enrolled/included in the study. 
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3- Predetermined Time interval: The first 14 records were analyzed since the duration of symptoms 
in AR is usually short (24):  
 In users who reported 7 to 14 days of data/symptom recording, we analyzed the total 
number of days of recording. 
 In users who reported over 14 days of data/symptom recording, only the first 14 were 
analyzed. 
 Data in duplicate (reporting, for the same day, 2 assessments) and multiplicate (reporting, 
for the same day, more than 2 assessments) have occurred (<10% of subjects).  
o For 7 records, any duplicate led to the withdrawal of the user. 
o For 8 records, 1 duplicate was allowed.  
o For 9 records, 2 duplicates were allowed.  
o For ≥10 records, 3 duplicates were allowed.  
o Thus, all users with less than 7 records were withdrawn. 
4- Medication possession ratio (modified MPR): We proposed that: 
 The same rhinitis treatment should be used during the time interval. No change in treatment 
for rhinitis was accepted and change represents an exclusion criteria. However, treatment 
for asthma was not considered and may vary. 
 Based on an accepted adherence level ≥70%, the minimum number of days of data 
recording/collection was determined (Table 1).  
 The modified MPR score was calculated as:  
                          
                                                            
  
 
5- Proportion of days covered over a time interval (modified PDC) 
Both continuous and discontinuous/intermittent reporting was monitored/evaluated. We defined 5 
levels of adherence depending on the modified PDC (Table 2) 
 The first and last days of data recording were identified and defined the time interval. 
 The dates of reporting within the time interval were assessed and counted. 
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 For duplicates or multiplicates, the number considered was the exact number (1, 2, 3…). 
 The modified PDC score was calculated as:   
                 
                                                          
  
 A number of recorded days greater than the time interval considered indicates that the user 
is taking more drugs than the initial treatment. We used two levels of PDC ≤ 1.25 (adherent 
user to time interval as defined by first and last days of recording and ≤ 1.5 (adherent or 
partly-adherent user to time interval as defined by first and last day of recording). 
Combining PDC ≤ 1.25 or ≤1.5 with MPR values, 4 groups were defined (Table 3). 
Biases 
In this study, we did not include the types of treatment used due to the significant variability 
between treatment recommendations in different countries and no clear pattern of treatment being 
easily identified from the data collected.    
Although MASK can be used to assess medication adherence, there are biases which should be 
considered: (i) In the literature, there is no clear definition on what is considered “adherent” or 
“non-adherent”, in terms of app usage; (ii) It is not known whether adherence with an app in any 
way reflects adherence with either medication or control; (iii) Users are anonymized, it is impossible 
to know how people use apps and the results may not reflect their daily AR management; (iv) It is 
possible that they take more medications than reported by the App as they may forget to register 
their daily symptoms.  
 
Sample Size 
In this exploratory study, all registered users who fulfilled the inclusion criteria over the study period 
were included in order to obtain the best possible estimates for the specified time window.  
 
Statistical analysis 
For normally distributed data, means and SD were used.  
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Results   
Characteristics of the user 
A total number of 12,143 users were registered in the Allergy Diary during the observational period. 
6,949 users reported at least one VAS data recording. A total of 64,566 VAS recordings were made. 
Among them, 1,887 users reported ≥ 7 VAS data (Figure 1). There were 888 (47%) males and 999 
(53%) females. They had a median age of 32 years (25-75 percentiles: 22-44 years). The repartition 
of user by country is presented in Table 4.  
 
Overall results 
Overall results are presented in Table 5. Only 136 (11.28%) users were adherent (MPR ≥70% and PDC 
≤ 1.25). In addition, 51 (4.23%) users were partly adherent (MPR ≥70% and PDC =1.50), and 176 
(14.60%) were switchers, defined as users who did not use the same medication but for the defined 
interval (MPR ≥70% and PDC > 1.50). On the other hand, 832 (69.05%) users were non-adherent to 
medications (MPR<70%). Of those, the largest group was non-adherent to medications and the time 
interval was increased in 442 (36.68%) users.  
 
For a number of days reported under 15 to 20, users were vastly non-adherent (MPR<70). On the 
other hand, above this level, users were more adherent to medications (PDC) than before. It 
therefore seems that users who reported VAS levels over 15 days are more likely to be adherent. 
Moreover, the median level of time interval was different between groups, suggesting that 
discontinuous treatment is associated with poorer medication adherence. 
 
Discussion   
Our study was characterized by information retrieved from patients from 22 countries. To our 
knowledge, this is the first study to perform an evaluation of medication adherence based on data 
retrieved from a mobile app using a routine way/real life setting. This study shows the very low 
adherence to treatment in AR patients in a real-life setting. 
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Strengths and limitations  
The strengths and limitations of this study are those of mobile technology, as previously discussed 
(12, 13, 25). There are potential measurement biases when using apps since the information 
collected is usually restricted and less complete than when using more detailed paper or web-based 
questionnaires. App users may be a selected subset and therefore not fully representative of all AR 
patients. Higher education or specific age ranges might apply. The study was not meant to be 
representative of the general population.  Precise patient characterization is impossible via an App 
used in real life, but every observational study using the Allergy Diary gave highly consistent results 
with a clear clinical perspective (11-14). Users self-reported the diagnosis of rhinitis but this was 
confirmed by the questionnaire on rhinitis and conjunctivitis symptoms included in the App. Mobile 
technology is likely to become an important tool to better understand and manage AR and asthma. 
Other limitations should also be considered.  Among a high number of users, only a relatively low 
number were constantly filling information on treatment in the app and we only considered users 
reporting over 6 days. We did not analyse the type of treatment due to its great variability. This will 
be done when more data become available and using machine learning approaches.  Another 
limitation is that the app is based on the unsupervised input of data. There is, therefore, a bias 
related to potentially missing data input. Nevertheless, our study took the opportunity of analysing 
real-world adherence and designing new methodologies for analysing such data. 
We did not include a questionnaire on medication adherence since users report their daily 
medications. 
 
Discussion of results 
Our data show that about 70% of AR patients filling data over 6 days (27.2% of the entire database) 
are non-adherent to medications. Only 11.3% of AR users filling data over 6 days were fully adherent 
to medications and time interval (MPR ≥70% and PDC ≤ 1.25). 
Few studies reported the prevalence of adherence in AR patients in the real-life context. 35% of 
patients were non-adherent for some time during the treatment and 38% indicated that they 
discontinued treatment when they felt better (26, 27). One study, carried out in the outpatient 
setting, suggests that a short message service (SMS) helps to improve AR treatment (28). 
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Adherence in randomized control trials is high but does not reflect the real-life situation (29,30) and 
alternative measurement of adherence in a real-life setting is needed. The best studies would be 
using electronic devices that count and record the drugs taken. However, these devices are 
expensive and, as such, not a viable solution for large studies in AR patients (31).  Considering that 
we live in an era of "digital revolution" and that a huge percentage of people have a smartphone, 
mobile applications appeared as a good alternative to improve patient control over their illness. 
Such m-health technology has enormous potential to be used as a reliable, cost-effective and usable 
tool, not only for AR, but also for other diseases (26,32,33). Although there are already some m-
health tools for allergic rhinitis, there are few studies evaluating their benefits and impact (26). 
There is a growing understanding of barriers to adherence and ways to overcome them. The 
development of mAdherence tools to explore barriers to maintaining engagement is growing and 
will be important in the development of mHealth interventions.  
There is no gold standard for measuring adherence to medication. There are mainly direct and 
indirect measures. All methods have their limitations, so it is highly recommended to combine more 
than one (34). In this study, we used a combination of MPR and PDC, the most used measures of 
secondary adherence. We defined adherence as MPR≥70% and PDC≤1.25. Results were grouped by 
PDC value by using a cut-off value of 1.25. Therefore, the resulting groups had PDC≤1.25 and 
PDC>1.25 respectively. It was possible to verify that, although with some differences, both follow 
the same trend. Under 15 to 20 days, patients were mostly non-adherent, and there are some 
theories that can explain this such as that for many patients AR is only intermittent and that the 
most troublesome symptoms can be managed with a short course of medication.  There are several 
subtypes of allergic rhinitis and, depending on the type and severity of the condition, the treatment 
may be different. AR can be described as a seasonal condition, therefore some patients may present 
persistent symptoms while others may present symptoms only when the allergen is present. On the 
other hand, above 15 days of VAS reported, patients tend to be more adherent, which may also be a 
result of more severe symptoms, leading to continuous treatment (27, 35) or to a better adherence 
in people reporting longer periods of use. It would be important to also study the attitudinal and 
behavioural clusters of individuals who continue to monitor and treat their AR above 15 days. 
Insights from research in asthma suggest that determining attitudinal clusters can provide insights 
into medication use and taking behaviour (36). All the participants were volunteers and anonymous, 
making them very remote from direct clinical input. Also, patients had no sense of being watched 
over (Hawthorn effect) which prevents a biased increase in adherence. In RCTs, adherence is likely to 
be much higher (37). Further research is needed to understand how patients can be motivated to 
use and app regularly and the role of the healthcare professional in suggesting that the app is used 
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as a means of assisting the patient to better understand their disease, monitor their symptoms and 
promote adherence. 
 
Conclusion   
This is the first paper to present adherence to AR treatment in a real-world setting from a European 
population sample. From a methodological point of view, this study highlights the opportunity to 
measure secondary adherence from an app (modified MPR and modified PDC). From a clinical point 
of view, this study gives the opportunity to discuss the gap that exists between theory and real word 
evidence, based on data from real practice, paving the way for a change management in allergic 
rhinitis. Further information will derive from the ongoing recruitment of Allergy Diary users. AR 
treatment is based on concepts that do not necessarily apply to real life. All recommendations 
propose a continuous treatment rather than an on-demand use (38). Our results show that 
adherence to treatment is low. The relative efficacy of continuous versus on-demand treatment for 
AR symptoms is still a matter of debate (39). In general, medical use (if achieved), non-anonymised 
and linked to the patients’ electronic health-records, may be higher because of the Hawthorn effect 
(40,41). However, a requirement to use the app to gain assistance should always be offered without 
any coercion. In other words, careful patient counselling is required. Moreover, in real life, patients 
rarely follow treatment indications (guidelines).  Finally, the use of such an app in the context of 
routine clinical care may present the opportunity to describe different Allergic Rhinitis (and Non-
Allergic Rhinitis) phenotypes, each of which may potentially have its own adherence pattern (to app 
usage and treatment) and may ultimately help to identify early on which patients might benefit from 
specialist assessment. 
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Table 1: Modified MPR cut-off for the assessment of medication adherence 
Time interval* Data on treatment* Medication adherence** 
(Modified MPR) 
7 5 71.4% 
8 6 75.0% 
9 7 77.8% 
10 7 70.0% 
11 8 72.7% 
12 9 75.0% 
13 10 76.9% 
14 10 71.4% 
*: Results expressed in days. **accepted cut-off for adherence is Modified MPR > 70% 
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Table 2: Number of days assessed to calculate the modified PDC   
Time 
interval* 
1 1.25 1.5 2 ≥2 
7 7 9 10 14 ≥15 
8 8 10 12 16 ≥17 
9 9 11 13 18 ≥19 
10 10 12 15 20 ≥21 
11 11 14 16 22 ≥23 
12 12 15 18 24 ≥25 
13 13 16 19 26 ≥27 
14 14 17 21 28 ≥29 
  *Results expressed in days 
 
 
Table 3: Definition of groups for adherence 
PDC Criteria MPR Criteria Descriptor  
≤ 1.25 or 1.5 ≥ 70% Users who always used the same 
medication for the defined time interval 
Adherent user 
≤ 1.25 or 1.5 <70% Users who always used the same 
medication but at a time greater than the 
defined time interval 
Partly adherent user 
>1.25 or 1.5 ≥ 70% Users who did not use the same 
medication for the defined interval 
Non-adherent user 
>1.25 or 1.5 < 70% Users who did not use the same 
medication and at a time greater than 
the defined time interval 
Non-adherent user 
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Table 4: Repartition of users per country 
Country Users 
Australia 11 
Austria 51 
Belgium 15 
Brazil 98 
Canada 3 
Czech Republic 3 
Denmark 19 
Finland 50 
France 53 
Germany 172 
Great Britain 97 
Greece 78 
Italy 228 
Lithuania 149 
Mexico 344 
Netherlands 46 
Poland 75 
Portugal 183 
Spain 157 
Sweden 15 
Switzerland  32 
Turkey 8 
Total 1887 
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Table 5: Overall results: number of users depending on MPR, PDC and duration of reporting 
Modified MPR   ≥70%       <70%   
Total users  
 
Modified PDC 1 1.25 1.5 2 >2 1 1.25 1.5 2 >2  
7 days  4 5 5 5 11 6 5 5 10 41 97   
8 days 3 3 6 5 11 2 14 8 4 41 97 
9 days 0 1 2 1 25 1 2 6 4 35 77 
10 days 5 2 0 2 8 2 4 6 10 32 71 
11 days 2 2 0 2 10 2 2 1 7 19 47 
12 days 0 2 0 2 5 0 2 18 3 12 44 
13 days 0 0 1 3 11 1 5 2 10 16 49 
14 days 0 3 1 7 8 2 3 7 6 17 54 
15 days 0 2 2 0 3 2 5 1 5 13 33 
16 days 0 1 2 1 6 4 3 6 3 9 35 
17 days 0 1 4 3 3 2 3 6 4 7 33 
18 days 2 2 1 0 3 4 1 1 2 7 23 
19 days 0 3 3 2 2 1 3 2 1 3 20 
20-22 days 5 6 2 4 3 7 10 12 4 14 67 
23-24 days 7 1 5 0 4 7 2 4 6 7 43 
25-29 days 2 5 3 1 4 10 15 16 3 8 67 
30-34 days 5 9 4 4 4 9 10 11 9 12 77 
35-39 days 3 3 1 1 0 12 8 7 5 8 48 
40-49 days 5 7 2 3 3 12 7 8 11 10 68 
50-59 days 3 5 0 2 1 7 13 4 5 3 43 
60-74 days 5 9 3 2 0 4 13 1 4 3 44 
75-99 days 4 6 4 1 0 6 10 5 4 4 44 
>100 days 1 2 0 0 0 3 7 0 0 1 14 
Total users  56 (4.68%) 80 (6.69%) 51 (4.26%) 51 (4.26%) 125 (10.46%) 106 (8.87%) 147 (12.30%) 137 (11.46%) 120 (10.04%) 322 (26.94%) 1195 (100%) 
Data are reported in user
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Figure 1: Flow chart of users 
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